Foghorn Therapeutics Stock Price Patterns
| FHTX Stock | USD 5.77 0.10 1.70% |
Momentum 65
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.28) | EPS Estimate Current Year (1.11) | EPS Estimate Next Year (1.00) | Wall Street Target Price 11.6667 | EPS Estimate Current Quarter (0.30) |
Using Foghorn Therapeutics hype-based prediction, you can estimate the value of Foghorn Therapeutics from the perspective of Foghorn Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Foghorn Therapeutics using Foghorn Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Foghorn using crowd psychology based on the activity and movement of Foghorn Therapeutics' stock price.
Foghorn Therapeutics Implied Volatility | 3.17 |
Foghorn Therapeutics' implied volatility exposes the market's sentiment of Foghorn Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Foghorn Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Foghorn Therapeutics stock will not fluctuate a lot when Foghorn Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Foghorn Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Foghorn because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Foghorn Therapeutics after-hype prediction price | USD 5.77 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Foghorn Therapeutics Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Foghorn Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Foghorn Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Foghorn Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Foghorn Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Foghorn Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Foghorn Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Foghorn Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Foghorn Therapeutics' historical news coverage. Foghorn Therapeutics' after-hype downside and upside margins for the prediction period are 0.06 and 11.48, respectively. We have considered Foghorn Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Foghorn Therapeutics is unstable at this time. Analysis and calculation of next after-hype price of Foghorn Therapeutics is based on 3 months time horizon.
Foghorn Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Foghorn Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Foghorn Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Foghorn Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.68 | 5.72 | 0.18 | 0.08 | 10 Events / Month | 5 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
5.77 | 5.77 | 0.00 |
|
Foghorn Therapeutics Hype Timeline
Foghorn Therapeutics is currently traded for 5.77. The entity has historical hype elasticity of -0.18, and average elasticity to hype of competition of -0.08. Foghorn is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is currently at 0.68%. %. The volatility of related hype on Foghorn Therapeutics is about 4612.9%, with the expected price after the next announcement by competition of 5.69. About 18.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.14. Foghorn Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 10 days. Check out Foghorn Therapeutics Basic Forecasting Models to cross-verify your projections.Foghorn Therapeutics Related Hype Analysis
Having access to credible news sources related to Foghorn Therapeutics' direct competition is more important than ever and may enhance your ability to predict Foghorn Therapeutics' future price movements. Getting to know how Foghorn Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Foghorn Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IMRX | Immuneering Corp | (1.14) | 8 per month | 0.00 | (0.01) | 8.12 | (5.64) | 67.18 | |
| PYXS | Pyxis Oncology | (0.26) | 13 per month | 0.00 | (0.07) | 17.05 | (15.41) | 70.66 | |
| ASMB | Assembly Biosciences | 0.00 | 0 per month | 0.00 | (0.08) | 5.85 | (6.65) | 18.53 | |
| ZURA | Zura Bio Limited | (0.26) | 11 per month | 4.26 | 0.14 | 9.32 | (7.00) | 33.15 | |
| ARCT | Arcturus Therapeutics Holdings | 0.19 | 9 per month | 0.00 | (0.14) | 6.10 | (6.72) | 15.98 | |
| SGMT | Sagimet Biosciences Series | 0.08 | 6 per month | 0.00 | (0.17) | 5.37 | (8.25) | 23.02 | |
| HUMA | Humacyte | 0.08 | 4 per month | 0.00 | (0.15) | 8.16 | (8.13) | 20.54 | |
| TRDA | Entrada Therapeutics | 0.25 | 11 per month | 2.11 | 0.24 | 6.98 | (4.00) | 15.00 | |
| ENTA | Enanta Pharmaceuticals | (0.26) | 2 per month | 2.61 | 0.1 | 5.67 | (3.59) | 15.79 | |
| VNDA | Vanda Pharmaceuticals | 0.08 | 12 per month | 4.93 | 0.10 | 11.39 | (6.34) | 39.51 |
Foghorn Therapeutics Additional Predictive Modules
Most predictive techniques to examine Foghorn price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Foghorn using various technical indicators. When you analyze Foghorn charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Foghorn Therapeutics Predictive Indicators
The successful prediction of Foghorn Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Foghorn Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Foghorn Therapeutics based on analysis of Foghorn Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Foghorn Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Foghorn Therapeutics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Interest Debt Per Share | 1.07 | 0.68 | 0.61 | 0.88 | Revenue Per Share | 0.81 | 0.41 | 0.37 | 0.28 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.